# HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.

> **NCT00147784** · PHASE3 · COMPLETED · sponsor: **Sorlandet Hospital HF** · enrollment: 10 (estimated)

## Conditions studied

- Opiate Dependence
- Hepatitis

## Interventions

- **DRUG:** Ribavirin
- **DRUG:** Pegylated Interferon

## Key facts

- **NCT ID:** NCT00147784
- **Lead sponsor:** Sorlandet Hospital HF
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-06
- **Final completion:** 2008-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2008-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00147784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00147784, "HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00147784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*